Search Results - "Murai, Hiroyuki"

Japanese clinical guidelines for myasthenia gravis: Putting into practice by Murai, Hiroyuki

“…Treatment of myasthenia gravis has depended largely on high‐dose corticosteroids for decades. Although this procedure remarkably reduced the mortality rate of…”
Get full text

AChR Antibody-Positive Myasthenia Gravis by Murai, Hiroyuki

“…Herein, we describe the mechanisms, diagnostic procedures, and treatment options for acetylcholine receptor (AChR) antibody-positive myasthenia gravis (MG)…”
Get more information

Therapeutic Strategies for Myasthenia Gravis by Murai, Hiroyuki

“…For years, the treatment of myasthenia gravis (MG) included high-dose oral steroids. This improved the mortality rate, but the adverse aspects of this…”
Get more information

Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders by Verschuuren, Jan JGM, Palace, Jacqueline, Murai, Hiroyuki, Tannemaat, Martijn R, Kaminski, Henry J, Bril, Vera

“…Myasthenia gravis and Lambert-Eaton myasthenic syndrome are antibody-mediated autoimmune diseases of the neuromuscular junction that usually present with…”
Get full text

Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic by Jacob, Saiju, Muppidi, Srikanth, Guidon, Amanda, Guptill, Jeffrey, Hehir, Michael, Howard, James F., Illa, Isabel, Mantegazza, Renato, Murai, Hiroyuki, Utsugisawa, Kimiaki, Vissing, John, Wiendl, Heinz, Nowak, Richard J.

Get full text

Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis by Matsushita, Takuya, Tateishi, Takahisa, Isobe, Noriko, Yonekawa, Tomomi, Yamasaki, Ryo, Matsuse, Dai, Murai, Hiroyuki, Kira, Jun-Ichi

“…Differences in cytokine/chemokine profiles among patients with neuromyelitis optica (NMO), relapsing remitting multiple sclerosis (RRMS), and primary…”
Get full text

A nationwide survey of combined central and peripheral demyelination in Japan by Ogata, Hidenori, Matsuse, Dai, Yamasaki, Ryo, Kawamura, Nobutoshi, Matsushita, Takuya, Yonekawa, Tomomi, Hirotani, Makoto, Murai, Hiroyuki, Kira, Jun-ichi

“…ObjectivesTo clarify the clinical features of combined central and peripheral demyelination (CCPD) via a nationwide survey.MethodsThe following characteristics…”
Get full text

COVID-19-associated risks and effects in myasthenia gravis (CARE-MG) by Muppidi, Srikanth, Guptill, Jeffrey T, Jacob, Saiju, Li, Yingkai, Farrugia, Maria E, Guidon, Amanda C, Tavee, Jinny O, Kaminski, Henry, Howard, James F, Cutter, Gary, Wiendl, Heinz, Maas, Matthew B, Illa, Isabel, Mantegazza, Renato, Murai, Hiroyuki, Utsugisawa, Kimiaki, Nowak, Richard J, Guidon, Amanda C, Tyagi, Alok, Sousa, Ana Paula, Amato, Anthony A, Pinto, Ashwin, Roy, Bhaskar, Carmichael, Caroline, Dodig, Dubravka, Burke, Georgina, Cutter, Gary R, Kaminski, Henry J, Wiendl, Heinz, Murai, Hiroyuki, Lee, Ikjae, Illa, Isabel, Guptill, Jeffrey, Howard, James F., Caress, James, Pritchard, Jane, Tavee, Jinny O, Vissing, John, Best, Kamla, Utsugisawa, Kimiaki, Ramezani, Mahtab, Maas, Mathew, Farrugia, Maria E, Hehir, Michael K, Kaku, Michelle, Esquivel, Natalia Jiménez, Gallagher, Paul, Maddison, Paul, Ambrose, Philip A, Mantegazza, Renato E, Nowak, Richard J, Do Campo, Rocio Vazquez, Jacob, Saiju, Saba, Sami, Nafissi, Shahriar, Itoyama, Shannon, Muppidi, Srikanth, Viegas, Stuart Viegas, Marshall, Victoria, Li, Yingkai Li

Get full text

Rationale for the clinical guidelines for myasthenia gravis in Japan by Murai, Hiroyuki, Utsugisawa, Kimiaki, Nagane, Yuriko, Suzuki, Shigeaki, Imai, Tomihiro, Motomura, Masakatsu

“…According to the 2014 Japanese clinical guidelines for myasthenia gravis, the most important priority in treatment is maintaining patients’ health‐related…”
Get full text

Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance by Murai, Hiroyuki, Suzuki, Shigeaki, Hasebe, Miki, Fukamizu, Yuji, Rodrigues, Ema, Utsugisawa, Kimiaki

“…Background: Eculizumab, a humanized monoclonal antibody targeted to terminal complement protein C5, is approved in Japan for treatment of patients with…”
Get full text

Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia Gravis by Howard, Jr, James F, Vissing, John, Gilhus, Nils E, Leite, M Isabel, Utsugisawa, Kimiaki, Duda, Petra W, Farzaneh-Far, Ramin, Murai, Hiroyuki, Wiendl, Heinz

“…Generalized myasthenia gravis (gMG) is an autoimmune disorder in which pathogenic autoantibodies damage the neuromuscular junction, causing disabling or…”
Get more information

The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert–Eaton myasthenic syndrome by Murai, Hiroyuki, Utsugisawa, Kimiaki, Motomura, Masakatsu, Imai, Tomihiro, Uzawa, Akiyuki, Suzuki, Shigeaki

“…The revised Japanese clinical guidelines for myasthenia gravis (MG) and Lambert–Eaton myasthenic syndrome (LEMS) were published in 2022. The notable points in…”
Get full text

Early detection of abnormal prion protein in genetic human prion diseases now possible using real-time QUIC assay by Sano, Kazunori, Satoh, Katsuya, Atarashi, Ryuichiro, Takashima, Hiroshi, Iwasaki, Yasushi, Yoshida, Mari, Sanjo, Nobuo, Murai, Hiroyuki, Mizusawa, Hidehiro, Schmitz, Matthias, Zerr, Inga, Kim, Yong-Sun, Nishida, Noriyuki

“…The definitive diagnosis of genetic prion diseases (gPrD) requires pathological confirmation. To date, diagnosis has relied upon the finding of the biomarkers…”
Get full text

MM2-type sporadic Creutzfeldt-Jakob disease: new diagnostic criteria for MM2-cortical type by Hamaguchi, Tsuyoshi, Sanjo, Nobuo, Ae, Ryusuke, Nakamura, Yosikazu, Sakai, Kenji, Takao, Masaki, Murayama, Shigeo, Iwasaki, Yasushi, Satoh, Katsuya, Murai, Hiroyuki, Harada, Masafumi, Tsukamoto, Tadashi, Mizusawa, Hidehiro, Yamada, Masahito

“…ObjectiveTo clinically diagnose MM2-cortical (MM2C) and MM2-thalamic (MM2T)-type sporadic Creutzfeldt-Jakob disease (sCJD) at early stage with high sensitivity…”
Get full text

Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod by Song, Zi-Ye, Yamasaki, Ryo, Kawano, Yuji, Sato, Shinya, Masaki, Katsuhisa, Yoshimura, Satoshi, Matsuse, Dai, Murai, Hiroyuki, Matsushita, Takuya, Kira, Jun-ichi

“…Fingolimod efficiently reduces multiple sclerosis (MS) relapse by inhibiting lymphocyte egress from lymph nodes through down-modulation of sphingosine…”
Get full text

International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r by Burns, Ted M., Sadjadi, Reza, Utsugisawa, Kimiaki, Gwathmey, Kelly G., Joshi, Amruta, Jones, Sarah, Bril, Vera, Barnett, Carolina, Guptill, Jeffrey T., Sanders, Donald B., Hobson-Webb, Lisa, Juel, Vern C., Massey, Janice, Gable, Karissa L, Silvestri, Nicholas J., Wolfe, Gil, Cutter, Gary, Nagane, Yuriko, Murai, Hiroyuki, Masuda, Masayuki, Farrugia, Maria Elena, Carmichael, Caroline, Birnbaum, Simone, Hogrel, Jean-Yves, Nafissi, Shahriar, Fatehi, Farzad, Ou, Changyi, Liu, Weibin, Conaway, Mark

“…ABSTRACT Introduction: The MG‐QOL15 is a validated, health‐related quality of life (HRQOL) measure for myasthenia gravis (MG). Widespread use of the scale gave…”
Get full text

Implication of circulating memory B cells in late-onset myasthenia gravis by Murai, Hiroyuki

“…Abstract Myasthenia gravis is a heterogeneous disease, and it presents various clinical differences according to the age of onset. Immunological backgrounds…”
Get full text

Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis by Oyama, Munenori, Okada, Kensuke, Masuda, Masayuki, Shimizu, Yuko, Yokoyama, Kazumasa, Uzawa, Akiyuki, Kawaguchi, Naoki, Ikeguchi, Ryotaro, Hoshino, Yasunobu, Hatano, Taku, Ozawa, Yukiko, Nakahara, Jin, Aizawa, Hitoshi, Kitagawa, Kazuo, Hattori, Nobutaka, Kuwabara, Satoshi, Murai, Hiroyuki, Suzuki, Shigeaki

“…Background: Eculizumab is a humanized monoclonal antibody that targets complement protein C5 and inhibits terminal complement-mediated damage at the…”
Get full text

Anti-LGI1 Encephalitis Developing Immunoglobulin Responsive Orthostatic Hypotension after Remission by Orimo, Kenta, Iwata, Nobue K, Kawai, Mizuho, Nakajima, Hideki, Takeda, Katsuhiko, Murai, Hiroyuki, Goto, Jun

“…Anti-leucine-rich glioma-inactivated 1 (LGI1) antibody is associated with limbic encephalitis. We herein report a patient with anti-LGI1 encephalitis who…”
Get full text

How should we use calcineurin inhibitors in myasthenia gravis? by Murai, Hiroyuki

“…Abstract Calcineurin inhibitors are approved for the treatment of myasthenia gravis in J apan. U tsugisawa et al. described the use of calcineurin inhibitors…”
Get full text